Investment Comparison: Bio-Rad vs. Charles River Laboratories
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: Fool
- Bio-Rad Financial Performance: In FY 2025, Bio-Rad achieved nearly $2.6 billion in revenue, reflecting a year-over-year growth of approximately 0.6%, with net income improving to $759.9 million from a prior year loss of $1.8 billion, indicating a robust recovery in life sciences and clinical diagnostics.
- Charles River Market Positioning: Charles River's revenue slightly declined to over $4.0 billion in FY 2025, with a net loss of approximately $144.3 million, highlighting challenges in drug discovery; however, its diverse client base mitigates reliance on any single customer, enhancing business resilience.
- Competitive Risk Analysis: Bio-Rad faces significant competition from larger peers like Thermo Fisher and Danaher, with about 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future performance.
- Future Outlook and Strategy: Bio-Rad aims to enhance cash flow and utilize share buybacks to improve per-share ratios, despite a projected slight revenue decline to $2.57 billion in FY 2026, while Charles River expects to return to profitability with a projected net income of $285 million by focusing on high-margin businesses and achieving $100 million in cost savings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIO
Wall Street analysts forecast BIO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 295.150
Low
340.00
Averages
340.00
High
340.00
Current: 295.150
Low
340.00
Averages
340.00
High
340.00
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Comparison: Bio-Rad vs. Charles River Laboratories
- Bio-Rad Financial Performance: In FY 2025, Bio-Rad achieved nearly $2.6 billion in revenue, reflecting a year-over-year growth of approximately 0.6%, with net income improving to $759.9 million from a prior year loss of $1.8 billion, indicating a robust recovery in life sciences and clinical diagnostics.
- Charles River Market Positioning: Charles River's revenue slightly declined to over $4.0 billion in FY 2025, with a net loss of approximately $144.3 million, highlighting challenges in drug discovery; however, its diverse client base mitigates reliance on any single customer, enhancing business resilience.
- Competitive Risk Analysis: Bio-Rad faces significant competition from larger peers like Thermo Fisher and Danaher, with about 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future performance.
- Future Outlook and Strategy: Bio-Rad aims to enhance cash flow and utilize share buybacks to improve per-share ratios, despite a projected slight revenue decline to $2.57 billion in FY 2026, while Charles River expects to return to profitability with a projected net income of $285 million by focusing on high-margin businesses and achieving $100 million in cost savings.
See More
Investment Choice Between Bio-Rad and Charles River Laboratories
- Financial Performance Comparison: Bio-Rad's FY 2025 revenue reached nearly $2.6 billion, reflecting a year-over-year growth of approximately 0.6%, with a net income of $759.9 million, indicating a significant recovery from a prior year net loss of $1.8 billion, showcasing its improving profitability.
- Market Competition Analysis: Bio-Rad faces significant competition in the diagnostics market from larger peers like Thermo Fisher and Danaher, with approximately 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future growth.
- Charles River's Business Restructuring: Charles River's FY 2025 revenue was just over $4.0 billion, a slight decline of about 1%, but net income is projected to rebound to $285 million in 2026 as management focuses on higher-margin efforts and identifies $100 million in cost savings.
- Investment Outlook Assessment: While Bio-Rad currently exhibits stronger profitability, Charles River appears cheaper and is further along in its business restructuring, making it a more attractive investment choice for 2026.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
Major Premarket Stock Movements in Key Companies
- Regeneron Drug Trial Failure: Regeneron Pharmaceuticals saw its stock plummet over 11% after its skin cancer treatment failed to meet goals in a late-stage trial, potentially undermining investor confidence and future R&D funding.
- Macy's Stock Surge: Macy's shares jumped nearly 4% in premarket trading after a regulatory filing revealed that Berkshire Hathaway initiated a small position valued at approximately $55 million, raising speculation about investment lieutenant Ted Weschler's involvement.
- Dominion Energy Acquisition News: Dominion Energy's stock surged more than 12% following NextEra Energy's announcement of an all-stock acquisition deal, which is expected to create the world's largest regulated electric utility, significantly enhancing market presence.
- Bio Rad Laboratories Stock Spike: Bio Rad Laboratories' shares rose 13% after a Wall Street Journal report indicated that activist investor Elliott Investment Management has built a sizable stake in the company, although the exact size and Elliott's strategic vision remain undisclosed.
See More
Elliott Investment Builds Stake in Bio-Rad to Boost Stock Price
- Investor Engagement: Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (BIO) with the intention of pushing for an increase in its underperforming stock price, indicating strong interest in the company's future performance.
- Strategic Investment Link: Elliott is also a major investor in Sartorius (SARTF), a German supplier of pharmaceutical and laboratory equipment, with Bio-Rad holding a strategic investment in Sartorius, suggesting that their business relationship may influence Bio-Rad's market performance.
- Financial Performance Decline: Bio-Rad recently lowered its 2026 revenue growth outlook to between -3% and +0.5%, reporting a first-quarter net loss of $527 million, reflecting the company's vulnerability in a changing market environment.
- Market Reaction: Bio-Rad's non-GAAP EPS of $1.89 missed expectations by $0.10, although its revenue of $592.1 million beat estimates by $3.24 million, highlighting market concerns regarding its future growth prospects.
See More
Investment Comparison: Bio-Rad vs. Charles River Laboratories
- Bio-Rad Financial Performance: In FY 2025, Bio-Rad achieved nearly $2.6 billion in revenue, reflecting a year-over-year growth of approximately 0.6%, with net income improving to $759.9 million from a prior year loss of $1.8 billion, indicating a robust recovery in life sciences and clinical diagnostics.
- Charles River Market Positioning: Charles River's revenue slightly declined to over $4.0 billion in FY 2025, with a net loss of approximately $144.3 million, highlighting challenges in drug discovery; however, its diverse client base mitigates reliance on any single customer, enhancing business resilience.
- Competitive Risk Analysis: Bio-Rad faces significant competition from larger peers like Thermo Fisher and Danaher, with about 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future performance.
- Future Outlook and Strategy: Bio-Rad aims to enhance cash flow and utilize share buybacks to improve per-share ratios, despite a projected slight revenue decline to $2.57 billion in FY 2026, while Charles River expects to return to profitability with a projected net income of $285 million by focusing on high-margin businesses and achieving $100 million in cost savings.
See More
Investment Choice Between Bio-Rad and Charles River Laboratories
- Financial Performance Comparison: Bio-Rad's FY 2025 revenue reached nearly $2.6 billion, reflecting a year-over-year growth of approximately 0.6%, with a net income of $759.9 million, indicating a significant recovery from a prior year net loss of $1.8 billion, showcasing its improving profitability.
- Market Competition Analysis: Bio-Rad faces significant competition in the diagnostics market from larger peers like Thermo Fisher and Danaher, with approximately 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future growth.
- Charles River's Business Restructuring: Charles River's FY 2025 revenue was just over $4.0 billion, a slight decline of about 1%, but net income is projected to rebound to $285 million in 2026 as management focuses on higher-margin efforts and identifies $100 million in cost savings.
- Investment Outlook Assessment: While Bio-Rad currently exhibits stronger profitability, Charles River appears cheaper and is further along in its business restructuring, making it a more attractive investment choice for 2026.
See More
Mixed US Stock Close as Oil Prices Volatile Amid Geopolitical Tensions
- Mixed Market Performance: The S&P 500 index fell by 0.07%, while the Dow Jones Industrial Average rose by 0.32%, and the Nasdaq 100 index decreased by 0.45%, indicating a divergence in market performance amid oil price volatility and geopolitical tensions.
- Oil Price Volatility: Crude oil prices surged to a three-week high on Monday due to Iran's comments on US demands being 'excessive and unrealistic', but prices fell sharply later when President Trump canceled a planned strike on Iran, highlighting the direct impact of geopolitical events on the market.
- Supportive Economic Data: The May NAHB housing market index rose by 3 to 37, exceeding expectations, which indicates resilience in the housing market and may provide some support for stocks.
- Weak Chinese Economic Indicators: China's April industrial production rose by 4.1% year-on-year, below the expected 6.0%, with retail sales and new home prices also underperforming, reflecting potential risks to global growth prospects.
See More
NextEra's Acquisition of Dominion Drives Stock Surge
- Acquisition Impact: NextEra Energy's announcement of an all-stock acquisition of Dominion Energy led to a more than 9% surge in Dominion's shares, positioning the combined entity as the world's largest regulated electric utility, significantly enhancing market presence.
- Cruise Industry Recovery: Viking Holdings' stock rose nearly 2% after Wells Fargo upgraded its rating to overweight, with 2027 advanced bookings up 31% from the previous year, indicating strong demand despite concerns over the U.S.-Iran conflict.
- Stock Buyback Plan: Cognizant Technology Solutions saw its shares increase by nearly 7% after doubling its stock repurchase target to approximately $2 billion for this year, which is expected to boost investor confidence and enhance shareholder value.
- Medical Device Investment: Boston Scientific's shares rose over 3% as it announced a $2 billion accelerated stock repurchase plan and a $1.5 billion investment in MiRus, allowing it to re-enter the transcatheter aortic valve replacement market, demonstrating strategic expansion in the medical field.
See More
Major Premarket Stock Movements in Key Companies
- Regeneron Drug Trial Failure: Regeneron Pharmaceuticals saw its stock plummet over 11% after its skin cancer treatment failed to meet goals in a late-stage trial, potentially undermining investor confidence and future R&D funding.
- Macy's Stock Surge: Macy's shares jumped nearly 4% in premarket trading after a regulatory filing revealed that Berkshire Hathaway initiated a small position valued at approximately $55 million, raising speculation about investment lieutenant Ted Weschler's involvement.
- Dominion Energy Acquisition News: Dominion Energy's stock surged more than 12% following NextEra Energy's announcement of an all-stock acquisition deal, which is expected to create the world's largest regulated electric utility, significantly enhancing market presence.
- Bio Rad Laboratories Stock Spike: Bio Rad Laboratories' shares rose 13% after a Wall Street Journal report indicated that activist investor Elliott Investment Management has built a sizable stake in the company, although the exact size and Elliott's strategic vision remain undisclosed.
See More
Elliott Investment Builds Stake in Bio-Rad to Boost Stock Price
- Investor Engagement: Activist investor Elliott Investment Management has built a significant stake in Bio-Rad Laboratories (BIO) with the intention of pushing for an increase in its underperforming stock price, indicating strong interest in the company's future performance.
- Strategic Investment Link: Elliott is also a major investor in Sartorius (SARTF), a German supplier of pharmaceutical and laboratory equipment, with Bio-Rad holding a strategic investment in Sartorius, suggesting that their business relationship may influence Bio-Rad's market performance.
- Financial Performance Decline: Bio-Rad recently lowered its 2026 revenue growth outlook to between -3% and +0.5%, reporting a first-quarter net loss of $527 million, reflecting the company's vulnerability in a changing market environment.
- Market Reaction: Bio-Rad's non-GAAP EPS of $1.89 missed expectations by $0.10, although its revenue of $592.1 million beat estimates by $3.24 million, highlighting market concerns regarding its future growth prospects.
See More
